With Yukon implementing a transitioning policy on April 3 to expand the use of biosimilar medicines in its public drug plan, it’s important for benefits plan sponsors that create a similar policy for their workplace plans to be clear in their communication and education with employees. “It’s never easy to switch a medication, especially when […]
As technology advances and plan members’ needs become more diverse, the relationship between benefits plan sponsors and providers is adapting to fit these changes. Sarah Beech, chief executive officer of benefits and consulting at Arthur J. Gallagher & Co., believes the trend of employees wanting more from their employers is the starting point for this […]
The Canadian Life and Health Insurance Association will now be working with participating insurers to collaborate on joint investigations into suspected benefits fraud schemes. This initiative builds on last year’s launch of a CLHIA-supported program that uses advanced artificial intelligence to identify fraudulent activity across a vast industry pool of claims data. “We’ve been working […]
RSA U.K. Pension Trustees, a subsidiary of Intact Financial Corp., is de-risking roughly £6.5 billion in U.K. defined benefit pension liabilities with an annuity buy-in. The deal, which will be completed with Pension Insurance Corp., will transfer all remaining economic and demographic risks associated with the Royal Insurance Group Pension Scheme and the Sal Pension Scheme, […]
Changes to Ontario’s policy on the use of biosimilars in its public drug plan could result in savings for private benefits plans if they choose to follow the provincial model, says Theresa Tran, a principal in group benefits at Eckler Ltd. Starting March 31, Ontario Drug Benefit recipients who are on an originator biologic will […]